Margolin v. Vital Pharmaceuticals CA4/1

CourtCalifornia Court of Appeal
DecidedMarch 15, 2013
DocketD060947
StatusUnpublished

This text of Margolin v. Vital Pharmaceuticals CA4/1 (Margolin v. Vital Pharmaceuticals CA4/1) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Margolin v. Vital Pharmaceuticals CA4/1, (Cal. Ct. App. 2013).

Opinion

Filed 3/15/13 Margolin v. Vital Pharmaceuticals CA4/1 NOT TO BE PUBLISHED IN OFFICIAL REPORTS California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

COURT OF APPEAL, FOURTH APPELLATE DISTRICT

DIVISION ONE

STATE OF CALIFORNIA

MATTHEW MARGOLIN, D060947

Plaintiff and Appellant,

v. (Super. Ct. No. 37-2010-00051561- CU-BT-NC) VITAL PHARMACEUTICALS, INC.,

Defendant and Respondent.

APPEAL from an order of the Superior Court of San Diego County, Earl H.

Maas III, Judge. Affirmed.

Matthew Margolin appeals an order denying his motion to certify a class of

purchasers of a dietary supplement called "NO Shotgun" in a false advertising action

against its manufacturer, Vital Pharmaceuticals, Inc. (Vital). Margolin alleged that Vital

falsely stated on product labels and its Web site that NO Shotgun contained an esterified

form of creatine that was more effective than the monohydrate form at building muscle,

increased muscle cell DNA, and induced formation of new muscle cells ("hyperplasia"). The trial court ruled Margolin had not presented sufficient evidence to establish several

of the procedural requirements for certification of the proposed class. We affirm.

I.

BACKGROUND

A. Margolin's Operative Complaint

In a second amended complaint, Margolin alleged that Vital manufactures,

markets and sells NO Shotgun, a creatine-based dietary supplement. According to

Margolin, creatine is a performance-enhancing substance that can increase strength and

power during high-intensity aerobic exercise. He alleged the target market for

NO Shotgun includes body builders, weight lifters, athletes and other consumers

conscious of health and fitness.

Margolin alleged Vital falsely claimed that NO Shotgun contained an esterified

form of creatine (creatine ethyl ester) that was superior to the common form (creatine

monohydrate) because the esterified form was better absorbed into the bloodstream and

delivered intact to muscle cells, where it could be transported across the muscle cell

membrane to " 'cause explosive muscle growth!' " Margolin also alleged Vital falsely

claimed that creatine ethyl ester, in combination with other ingredients in NO Shotgun,

increased muscle cell DNA and caused muscle cell hyperplasia. According to Margolin,

the scientific study that Vital cited to support its "outrageous and false claims" did not

use criteria generally acceptable as reliable in the scientific community. Margolin further

alleged that Vital priced NO Shotgun two to three times higher than other creatine-based

2 dietary supplements, even though scientific studies have shown the esterified form of

creatine is greatly inferior to creatine monohydrate at promoting muscle growth.

In describing his own experience with NO Shotgun, Margolin alleged that he read

the product label and marketing information on Vital's Web site; relied on Vital's claims

about the efficacy of NO Shotgun; used the product for almost two years; but noticed no

extraordinary increase in muscle mass or any effect that was not attributable to his normal

workout regimen. He further alleged that in reliance on Vital's false claims concerning

the superiority of creatine ethyl ester over creatine monohydrate at building muscle, he

paid two or three times as much for NO Shotgun as he would have paid for other similar

products containing creatine monohydrate. "In short," Margolin complained,

"N.O. Shotgun is yet another 'snake oil' product based on non-existent science, and thus

does not warrant a price more than the price charged for regular creatine products."

Margolin sued Vital for violations of the Consumers Legal Remedies Act (CLRA;

Civ. Code, § 1750 et seq.), the unfair competition law (UCL; Bus. & Prof. Code, § 17200

et seq.), and the false advertising law (FAL; Bus. & Prof. Code, § 17500 et seq.). He also

asserted claims for "common law restitution,"1 breach of express warranty, and breach of

1 "There is no freestanding cause of action for 'restitution' in California." (Munoz v. MacMillan (2011) 195 Cal.App.4th 648, 661.) Rather, restitution is a remedy that may be awarded to prevent unjust enrichment when the defendant has obtained some benefit from the plaintiff through fraud, duress, conversion or similar misconduct. (McBride v. Boughton (2004) 123 Cal.App.4th 379, 387-388.) Restitution is authorized by the UCL and FAL. (Bus. & Prof. Code, §§ 17203, 17535; Cortez v. Purolator Air Filtration Products Co. (2000) 23 Cal.4th 163, 177, fn. 10.) Because Margolin sought "common law restitution" on the basis of the same conduct that allegedly violated the UCL and 3 implied warranty. On behalf of himself and a putative class of California purchasers of

NO Shotgun, Margolin sought (1) to enjoin the "ongoing deceptions" contained in Vital's

product labeling and Web site marketing, and (2) "to recover for the economic harms

suffered by [Margolin] and the putative class as a result of [Vital's] false and misleading

advertising claims" that induced them to buy NO Shotgun.

B. Margolin's Motion for Class Certification

1. Initial Motion Papers

Margolin moved to certify a class of all persons residing in California who

purchased NO Shotgun at any time during the period from February 23, 2006, through

the date of certification of a class in this action. Margolin argued certification of such a

class was appropriate because: (1) there were at least 100 class members who were

readily identifiable by their purchase of NO Shotgun; (2) common questions regarding

the falsity and materiality of Vital's labeling and Web site marketing statements

predominated over individual questions; (3) his claim was typical of the class because

Vital deceived him and absent class members in the same manner; and (4) he would

adequately represent the class because he had no conflicts with other class members

regarding the litigation, and his counsel was experienced in prosecuting class actions.

In support of his motion for class certification, Margolin submitted several

declarations. In his own, Margolin stated that he had purchased NO Shotgun several

times from 2008 to 2010 in reliance on Vital's claims that it caused muscle cell

FAL, we consider his demand for restitution as part of those claims, not as a separate claim. 4 hyperplasia and contained an esterified form of creatine that provided better results than

creatine monohydrate. Margolin also stated that, during the two years he used

NO Shotgun, he noticed no extraordinary increase in muscle mass or other effects not

attributable to his normal workout regimen, and would not have purchased the product

had he known it would not perform as Vital had advertised. Margolin's counsel

submitted a declaration in which she described her experience litigating class actions and

attached several exhibits, including a label from NO Shotgun and a printout of

information from Vital's Web site. Margolin also submitted declarations from two expert

witnesses. One expert, a former employee of the Food and Drug Administration,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brinker Restaurant Corp. v. Superior Court
273 P.3d 513 (California Supreme Court, 2012)
Kennedy v. Domerque
137 Cal. App. Supp. 2d 849 (California Court of Appeal, 1955)
Mirkin v. Wasserman
858 P.2d 568 (California Supreme Court, 1993)
Cortez v. Purolator Air Filtration Products Co.
999 P.2d 706 (California Supreme Court, 2000)
Occidental Land, Inc. v. Superior Court
556 P.2d 750 (California Supreme Court, 1976)
Vasquez v. Superior Court
484 P.2d 964 (California Supreme Court, 1971)
Rose v. Superior Court
569 P.2d 727 (California Supreme Court, 1977)
Richmond v. Dart Industries, Inc.
629 P.2d 23 (California Supreme Court, 1981)
Lazar v. Superior Court
107 P.2d 249 (California Supreme Court, 1940)
City of San Jose v. Superior Court
525 P.2d 701 (California Supreme Court, 1974)
Daar v. Yellow Cab Co.
433 P.2d 732 (California Supreme Court, 1967)
In Re Tobacco II Cases
207 P.3d 20 (California Supreme Court, 2009)
Guidotti v. County of Yolo
214 Cal. App. 3d 1552 (California Court of Appeal, 1989)
National Solar Equipment Owners' Ass'n v. Grumman Corp.
235 Cal. App. 3d 1273 (California Court of Appeal, 1991)
Bauman v. Islay Investments
45 Cal. App. 3d 797 (California Court of Appeal, 1975)
Rose v. City of Hayward
126 Cal. App. 3d 926 (California Court of Appeal, 1981)
Osborne v. Subaru of America, Inc.
198 Cal. App. 3d 646 (California Court of Appeal, 1988)
Williams v. Beechnut Nutrition Corp.
185 Cal. App. 3d 135 (California Court of Appeal, 1986)
Hebbard v. Colgrove
28 Cal. App. 3d 1017 (California Court of Appeal, 1972)
Hamwi v. Citinational-Buckeye Investment Co.
72 Cal. App. 3d 462 (California Court of Appeal, 1977)

Cite This Page — Counsel Stack

Bluebook (online)
Margolin v. Vital Pharmaceuticals CA4/1, Counsel Stack Legal Research, https://law.counselstack.com/opinion/margolin-v-vital-pharmaceuticals-ca41-calctapp-2013.